Co-regulated expression of matrix metalloproteinase-2 and transforming growth factor-ß in melanoma development and progression

Oncology Reports

Volumn 24, Issue 1, 2010, Pages 81-87

  Malaponte, Grazia ^a   Zacchia, Alessandra ^a   Bevelacqua, Ylenia ^b   Marconi, Andrea ^a   Perrotta, Rosario ^b   Mazzarino, Maria Clorinda ^a   Cardile, Vera ^a   Stivala, Franca ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b CANNIZZARO HOSPITAL   (Italy)

Author keywords

Cytokines; Melanoma; MMP 2; TGF

Indexed keywords

GELATINASE A; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; BLOOD; CASE CONTROL STUDY; CELL TRANSFORMATION; DISEASE COURSE; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SKIN NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 77952989996     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000831     Document Type: Article

References (43)

1. Singh H, Sethi S, Raber M and Petersen LA: Errors in cancer diagnosis: current understanding and future directions. J Clin Oncol 25: 5009-5018, 2007. (Pubitemid 350220435)
2. Utikal J, Schadendorf D and Ugurel S: Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res 298: 469-477, 2007. (Pubitemid 46295062)
3. Gogas H, Eggermont AM, Hauschild A, et al: Biomarkers in melanoma. Ann Oncol 20 (Suppl. 6): vi8-13, 2009.
4. Alexandrow MG and Moses HL: Transforming growth factor beta and cell cycle regulation. Cancer Res 55: 1452-1457, 1995.
5. Wakefield LM and Roberts AB: TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12: 22-29, 2002.
6. Akhurst RJ and Balwain A: Genetic events and the role of TGF-β in epithelial tumor progression. Pathology 187: 82-90, 1999.
7. Oft M, Peli J, Rudaz C, Schwarz H, Beug H and Reichmann E: TGF-β and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10: 2462-2477, 1996. (Pubitemid 26341881)
8. Cui W, Fowlis DJ, Bryson S, et al: TGF beta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86: 531-542, 1996. (Pubitemid 26299485)
9. Reed JA, McNutt NS, Prieto VG and Albino AP: Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol 145: 97-104, 1994.
10. Javelaud D, Alexaki VI and Mauviel A: Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res 21: 123-132, 2008. (Pubitemid 351551229)
11. Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U and Orfanos CE: Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 77: 1492-1494, 1998. (Pubitemid 28190751)
12. Lin SW, Lee MT, Ke FC, et al: TGF-beta stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103. Clin Exp Metastasis 18: 493-499, 2000.
13. Dehnavi E, Soheili ZS, Samiei S, Ataei Z and Aryan H: The effect of TGF-beta2 on MMP-2 production and activity in highly metastatic human bladder carcinoma cell line 5637. Cancer Invest 27: 568-574, 2009.
14. Taipale J, Saharinen J and Keski-Oja J: Extracellular matrix associated transforming growth factor beta: role in cancer cell growth and invasion. Adv Cancer Res 75: 87-134, 1998. (Pubitemid 28429034)
15. Hofmann UB, Westphal JR, van Muijen GN and Ruiter DJ: Matrix metalloproteinases in human melanoma. J Invest Dermatol 115: 337-344, 2000.
16. Rundhaug JE: Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9: 267-285, 2005.
17. Väsäen A, Tuominen H, Kallioinen M and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 180: 283-289, 1996. (Pubitemid 26393677)
18. Hofmann UB, Westphal JR, Waas ET, Becker JC, Ruiter DJ and van Muijen GN: Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol 115: 625-632, 2000.
19. John A and Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7: 14-23, 2001. (Pubitemid 32591662)
20. Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ and van Muijen GN: Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membranetype 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 191: 245-256, 2000.
21. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G and Gress TM: TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 93: 204-211, 2001. (Pubitemid 32574276)
22. Morton DM and Barrack ER: Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55: 2596-2602, 1995.
23. Gorsch SM, Memoli VA, Stukel TA, et al: Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 52: 6949-6952, 1992.
24. Wollina U, Hipler UC, Knoll B, Graefe T, Kaatz M and Kirsc K: Serum matrix metalloproteinase-2 in patients with malignant melanoma. J Cancer Res Clin Oncol 127: 631-635, 2001. (Pubitemid 32778654)
25. Väsäen A, Kallioinen M, Taskinen PJ and Turpeenniemi-Hujanen T: Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 186: 51-58, 1998. (Pubitemid 28407488)
26. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648, 2001.
27. Iida J and McCarthy JB: Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-beta. Melanoma Res 17: 205-213, 2007. (Pubitemid 47067078)
28. Dang D, Yang Y, Li X, et al: Matrix metalloproteinases and TGFbeta1 modulate oral tumor cell matrix. Biochem Biophys Res Commun 316: 937-942, 2004. (Pubitemid 38368043)
29. Sun L, Diamond ME, Ottaviano AJ, Joseph MJ, Ananthanarayan V and Munshi HG: Transforming growth factor-beta 1 promotes matrix metalloproteinase-9- mediated oral cancer invasion through snail expression. Mol Cancer Res 6: 10-20, 2008. (Pubitemid 351378162)
30. Wick W, Platten M and Weller M: Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neurooncol 53: 177-185, 2001. (Pubitemid 33034690)
31. Konrad L, Scheiber JA, Schwarz L, Schrader A and Hofmann R: TGF-beta1 and TGF-beta2 strongly enhance the secretion of plasminogen activator inhibitor-1 and matrix metalloproteinase-9 of the human prostate cancer cell line PC-3. Regul Pept 155: 28-32, 2009.
32. Kim ES, Kim MS and Moon A: TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells. Int J Oncol 25: 1375-1382, 2004.
33. Yabushita H, Narumiya H, Hiratake K, et al: The association of transforming growth factor-beta 1 with myometrial invasion of endometrial carcinomas through effects on matrix metalloproteinase. J Obstet Gynaecol Res 26: 163-170, 2000. (Pubitemid 30410213)
34. Van Belle P, Rodeck U, Nuamah I, Halpern AC and Elder DE: Melanoma-associated expression of transforming growth factorbeta isoforms. Am J Pathol 148: 1887-1894, 1996.
35. Rodeck U, Bossler A, Graeven U, et al: Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 54: 575-581, 1994. (Pubitemid 24053203)
36. Hussein MR: Transforming growth factor-beta and malignant melanoma: molecular mechanisms. J Cutan Pathol 32: 389-395, 2005.
37. Curran S and Murray GI: Matrix metalloproteinases in tumor invasion and metastasis. J Pathol 189: 300-308, 1999. (Pubitemid 29489213)
38. Capon F, Emonard H, Hornebeck W, Maquart FX and Bernard P: Expression and activation of pro-gelatinase A by human melanoma cell lines with different tumorigenic potential. Clin Exp Metastasis 17: 463-469, 1999. (Pubitemid 30182739)
39. Kahari V and Saarialho-Kere U: Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 31: 34-45, 1999. (Pubitemid 29134483)
40. Redondo P, Lloret P, Idoate M and Inoges S: Expression and serum levels of MMP-2 and MMP-9 during human progression. Clin Exp Dermatol 30: 541-545, 2005. (Pubitemid 41076024)
41. Vuoristo MS, Kellokumpu-Lehtinen P, Parvinen LM, et al: Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma. Acta Oncol 39: 877-879, 2000.
42. Simonetti O, Lucarini G, Brancorsini D, et al: Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 95: 1963-1970, 2002.
43. Walker RA and Woolley DE: Immunolocalisation studies of matrix metalloproteinases-1, -2 and -3 in human melanoma. Virchows Arch 435: 574-579, 1999.